It’s been a wild Monday for Amarin (AMRN). The biopharma company’s stock price is soaring on the readout of a large clinical trial showing its proprietary, prescription formulation of fish oil cut the risk of bad cardiovascular events like heart attacks and stroke in patients by an astounding 25 percent.
With these new study results, Amarin and its omega-3 capsules — sold under the brand name Vascepa — are poised to make heart-medicine history. What was a niche commercial product may soon become a gold standard, add-on therapy to statins prescribed to millions of Americans. Billions of dollars in sales are potentially up for grabs for Amarin.